Phathom Pharma Exceeds Expectations Phathom Pharma recently delivered a solid earnings surprise, beating EPS estimates by $0.34 and topping revenue forecasts. The stock closed regular trading at $12.32. Even though shares have taken a 21.13% hit over the last three months, the bigger picture tells a distinctly different story. Over the past year, the stock is actually up a massive 113.89%. Wall Street analysts are clearly taking notice of this momentum. The company snagged four upward EPS revisions in the last 90 days without a single downgrade, though InvestingPro currently views its overall financial health as just “average” based on recent metrics. As investors weigh whether to buy into PHAT right now, many are turning to data-driven tools. Platforms like ProPicks AI evaluate stocks against thousands of others using over 100 financial data points to find the best risk-reward setups based on fundamentals and momentum, similar to how the technology previously identified massive winners like Super Micro Computer (+185%) and AppLovin (+157%).
Medicus Pharma Focuses on Clinical Growth Meanwhile, Medicus Pharma Ltd (MDCX) is quietly navigating its own path in the healthcare and biotechnology sector. As of 9:48 AM on February 26, the stock was trading at $1.24, up slightly by a couple of cents to mark a 1.64% gain for the session. Trading volume was notably light early on, with just 3,900 shares moving compared to an average volume of over 376,000. As a clinical-stage holding company, Medicus continues to focus its efforts on funding and accelerating novel life science companies through FDA-approved trials. Their primary mission remains tackling unmet medical needs to improve patient safety and treatment efficacy. The $30.15 million market cap company currently shows a wide 52-week range stretching from $0.92 up to $8.94, though shares recently changed hands in a very tight daily band between $1.23 and $1.24.
